Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4068)
All Articles published online
|
Dec 28, 2006 (publication date) through Nov 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chen JY, Li F. Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier. World J Gastroenterol 2006; 12(48): 7774-7778 [PMID: 17203519 DOI: 10.3748/wjg.v12.i48.7774] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i48/7774.htm |
| Number | Citing Articles |
| 1 |
Irina Sominskaya, Dace Skrastina, Andris Dislers, Denis Vasiljev, Marija Mihailova, Velta Ose, Dzidra Dreilina, Paul Pumpens. Construction and Immunological Evaluation of Multivalent Hepatitis B Virus (HBV) Core Virus-Like Particles Carrying HBV and HCV Epitopes. Clinical and Vaccine Immunology 2010; 17(6): 1027 doi: 10.1128/CVI.00468-09
|
| 2 |
Michiel Etienne Janssens, Dirk Geysen, Katleen Broos, Ine De Goeyse, Johan Robbens, Filip Van Petegem, Jean-Pierre Timmermans, Yves Guisez. Folding properties of the hepatitis B core as a carrier protein for vaccination research. Amino Acids 2010; 38(5): 1617 doi: 10.1007/s00726-009-0365-1
|
| 3 |
Farshad Hemmati, Mohsen Hemmati-Dinarvand, Marziye Karimzade, Daria Rutkowska, Mohammad Hadi Eskandari, Sayyad Khanizadeh, Alireza Afsharifar. Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2. Biotechnology Letters 2022; 44(1): 45 doi: 10.1007/s10529-021-03211-0
|
| 4 |
Verena Schlaphoff, Christoph S. Klade, Bernd Jilma, Sandra B. Jelovcan, Markus Cornberg, Erich Tauber, Michael P. Manns, Heiner Wedemeyer. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 2007; 25(37-38): 6793 doi: 10.1016/j.vaccine.2007.06.026
|
| 5 |
David F. Gardiner, Talia Rosenberg, Jerry Zaharatos, David Franco, David D. Ho. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 2009; 27(27): 3598 doi: 10.1016/j.vaccine.2009.03.058
|
| 6 |
Maryam Moradi Vahdat, Farshad Hemmati, Abozar Ghorbani, Daria Rutkowska, Alireza Afsharifar, Mohammad Hadi Eskandari, Nahid Rezaei, Ali Niazi. Hepatitis B core-based virus-like particles: A platform for vaccine development in plants. Biotechnology Reports 2021; 29: e00605 doi: 10.1016/j.btre.2021.e00605
|
| 7 |
Yali Zhang, Wenzheng Jiang, Yan Fan, Jiejun Wen, Wenli Hao, Min Qian. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant. Journal of Virological Methods 2008; 153(2): 142 doi: 10.1016/j.jviromet.2008.07.013
|
| 8 |
Kenny Roose, Sarah De Baets, Bert Schepens, Xavier Saelens. Hepatitis B core–based virus–like particles to present heterologous epitopes. Expert Review of Vaccines 2013; 12(2): 183 doi: 10.1586/erv.12.150
|
| 9 |
Javad Khodaei‐Mehr, Samaneh Tangestanizadeh, Ramin Vatankhah, Mojtaba Sharifi. Optimal neuro‐fuzzy control of hepatitis C virus integrated by genetic algorithm. IET Systems Biology 2018; 12(4): 154 doi: 10.1049/iet-syb.2017.0074
|